<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82302">
  <stage>Registered</stage>
  <submitdate>25/09/2007</submitdate>
  <approvaldate>27/09/2007</approvaldate>
  <actrnumber>ACTRN12607000496415</actrnumber>
  <trial_identification>
    <studytitle>Laparoscopic investigation of endometriosis using confocal endomicroscopy.</studytitle>
    <scientifictitle>Women with symptoms of endometriosis who are indicated for diagnostic or therapeutic surgery undergo in vivo microscopic imaging of endometriosis lesions for comparison with conventional histopathological analysis of biopsied lesions to assess the diagnostic potential of endomicroscopy in identifying lesions prior to therapeutic intervention.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Endometriosis.</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Confocal endomicroscopy
In vivo microscopic imaging using an intravenously administered fluorescent contrast agent (Fluorescein Sodium 10%), is performed during the participant's therapeutic or diagnostic surgery. Depending upon the number of lesions identified, endomicroscopic imaging is expected to add 10-20 minutes to each participant's laparoscopic surgery (1 session per participant).</interventions>
    <comparator>Suspected endometriosis lesions will be biopsied at the time of laparoscopy, immediately prior to surgical intervention (e.g. ablation, excision) for conventional histopathological confirmation of the tissue type (endometriosis - uterine epithelium, endosalpingiosis - Fallopian tube epithelium, fibrosis, other normal tissue).</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Endomicroscopy images from each lesion.</outcome>
      <timepoint>During laparoscopy approximately 20-30 images per lesion will be collected  to document the surface and subsurface cellular structure.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Macroscopic appearance of each lesion.</outcome>
      <timepoint>At laparoscopy, the macroscopic appearance of each lesion will be recorded and assessed immediately prior to collecting endomicroscopy images.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Conventional histology from each lesion.</outcome>
      <timepoint>Histopathological analysis of each biopsied lesion will be available from pathology approximately 1 week post laparoscopy.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Accuracy of endomicroscopy for predicting histology based on a simple image classification system.</outcome>
      <timepoint>Predictions of histology will be made during laparoscopy immediately after images of each lesion are obtained and before the conventional histology results are known (accuracy of predictions will be measured in the second series of patients only, once data from the first 8 patients are analysed).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women of reproductive age with symptoms consistent with endometriosis (including painful periods, pelvic pain, painful intercourse) who are indicated for diagnostic or therapeutic laparoscopy.
English speaking background.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women under the age of 18 years.
Patients with inadequate English.
Patients who are mentally or legally incapacitated or unable to give informed consent.
Allergy or prior adverse reaction to Fluorescein Sodium.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3053</postcode>
    <postcode>3121</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Optiscan Pty Ltd</primarysponsorname>
    <primarysponsoraddress>15-17 Normanby Road
Notting Hill VIC 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Optiscan Pty Ltd</fundingname>
      <fundingaddress>15-17 Normanby Road
Notting Hill VIC 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to evaluate the diagnostic accuracy of a new cellular imaging device for identifying endometriosis lesions during surgery which require treatment or removal.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Women's Hospital Human Research &amp; Ethics Committee</ethicname>
      <ethicaddress>132 Grattan St
Carlton VIC 3053</ethicaddress>
      <ethicapprovaldate>22/08/2007</ethicapprovaldate>
      <hrec>07/19</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Martin Healey</name>
      <address>Head of Unit
Gynaecology 2
The Royal Women's Hospital
132 Grattan St
Carlton VIC 3053</address>
      <phone>+613 94259833</phone>
      <fax>+613 94278295</fax>
      <email>kathandmutt@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Elise Murr</name>
      <address>15-17 Normanby Rd
Notting Hill VIC 3168</address>
      <phone>+613 95383333</phone>
      <fax>+613 95627742</fax>
      <email>elisem@optiscan.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Elise Murr</name>
      <address>15-17 Normanby Road
Notting Hill VIC 3168</address>
      <phone>+613 95383333</phone>
      <fax>+613 95627742</fax>
      <email>elisem@optiscan.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>